“…Currently, the PDT alone can hardly achieve satisfactory cancer immunotherapy due to the following intractable problems: (1) most PSs possess poor tumor targeting and accumulation capability, low payloads, easy aggregation, photoinduced quenching, etc. ; , (2) the GSH levels in cancer cells are much higher (100–1000 fold) than in normal cells, and the overexpressed GSH serves as an antioxidant to scavenge the produced ROS under light irradiation; , (3) tumor hypoxia is recognized as a typical feature of solid tumors that severely reduces the therapeutic efficacy because of the O 2 -dependent nature of PDT. − To address the first problem mentioned above, metal–organic frameworks (MOF) that integrate a photosensitizer into the periodic structure have opened a new door for PDT of tumors due to a high PS loading ratio, facile diffusion of singlet oxygen ( 1 O 2 ), intrinsic biodegradability, controllable sizes/shapes, and inhibited photoinduced quenching of the photosensitizer. − According to the second problem of PDT, tremendous efforts have been devoted to developing GSH-depleting materials. For instance, copper ion-based nanocomplexes (Cu 2+ - g -C 3 N 4 , Cu 2+ MOF, Cu-TCPP), manganese ion-based nanosystems (MnO 2 , MnFe 2 O 4 @MOF core–shell nanostructure, Mn III -sealed MOF nanostructure), Fe-doped nanoplatforms, and enzymes were prepared to intracellularly decrease GSH levels and thus enhance the PDT effect. − To solve the intrinsic bottleneck of PDT around tumor hypoxia, researchers have explored different methods to ameliorate tumor hypoxia, including the direct delivery of oxygen, in situ generation of oxygen (catalase, MnO 2 , Pt nanoparticles, CaO 2 , carbon nitride, carbon dots), and the inhibition of tumor vascular recurrence. − As a low-cost, efficient, and stable catalyst, metal nanomaterials are widely applied in biosensors, cancer therapy, and environmental protection.…”